Core Insights - Vivos Therapeutics, Inc. is a medical device and healthcare services company focused on diagnosing and treating sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [1][3] - The company will participate in a fireside chat to discuss its strategic business model pivot, operational execution, market opportunities, competitive environment, and growth strategies [2] Company Overview - Vivos Therapeutics, founded in 2016 and based in Littleton, Colorado, specializes in innovative diagnostic and treatment methods for breathing and sleep issues related to dentofacial abnormalities [3][5] - The company's devices are FDA-cleared for treating all severity levels of OSA in adults and moderate-to-severe OSA in children aged 6 to 17 [3] - Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for severe OSA treatment in adults and the first for moderate to severe OSA in children [3] Market Context - OSA affects over 1 billion people globally, with 90% undiagnosed, linking it to serious chronic health conditions [4] - Traditional OSA treatments, such as CPAP, often fail to address the root causes of the disorder, indicating a significant market opportunity for innovative solutions [4] Treatment Approach - Vivos employs a proprietary treatment method known as The Vivos Method, which is nonsurgical, noninvasive, and nonpharmaceutical, aiming to provide effective solutions for OSA patients [6]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Data and Key Metrics Changes - For Q3 2025, revenue increased by 76% to $6.8 million compared to $3.9 million in Q3 2024, and 78% sequentially from Q2 2025 [8] - For the nine months ended September 30, 2025, revenue increased by approximately $2.3 million, or 20%, to $13.6 million compared to $11.3 million for the same period in 2024 [9] - Gross profit for Q3 2025 increased to approximately $3.9 million, with a gross margin of 58%, slightly down from 60% in Q3 2024 [11] - Net loss increased to $5.4 million in Q3 2025 and $14.3 million for the first three quarters of 2025 [12] Business Line Data and Key Metrics Changes - The increase in revenue was driven by a $2.2 million increase in OSA sleep testing services primarily from the Sleep Center of Nevada (SCN) and $1.3 million from new treatment centers [8] - VIP enrollment revenue from the legacy business model decreased by $800,000, indicating a shift towards the new model [9] Market Data and Key Metrics Changes - The company is currently servicing significantly less than 40% of the potential new patients being tested each month at SCN, indicating substantial growth potential [23] - Over 210,000 OSA patients have been tested by SCN providers since 2019, with many potential patients dissatisfied with CPAP units [23] Company Strategy and Development Direction - The strategic pivot towards acquiring sleep medical practices and forming alliances is aimed at increasing market penetration and financial returns [18] - The establishment of Sleep and Airway Medicine Centers (SAMC) in Nevada is part of the strategy to provide comprehensive treatment options for OSA patients [20] - Future initiatives include expanding diagnostic and treatment services, establishing a pediatric OSA program, and collaborating with specialty medical groups [29] Management's Comments on Operating Environment and Future Outlook - Management views Q3 2025 as a watershed quarter, indicating the company's ability to monetize its technology for treating sleep-related disorders [15] - The company expects revenue growth to continue as new dental providers and nurse practitioners are onboarded, which will optimize revenue generation [39] - Management anticipates that the SAMC operations will achieve contribution margins of 50%-60% at steady-state [43] Other Important Information - The company has secured $14.2 million in net cash from financing activities, which will support its growth initiatives [13] - The acquisition of SCN has allowed the company to recognize new revenue streams from OSA diagnostic and treatment services [57] Q&A Session Summary Question: How should sales be modeled for the next few quarters? - Management expects top-line revenues to continue to grow as new providers are deployed, with a ramp-up period of three to six months for optimal revenue levels [39][40] Question: What are the reasonable operating expenses for the next quarters? - SAMC operations are expected to achieve contribution margins of 50%-60% at steady-state, with current expenses being higher due to upfront investments [43] Question: Update on cash flow break-even goals? - The goal is to achieve cash flow break-even, with expectations that profits from SAMC operations will contribute to this goal in the near future [46] Question: How should investors view the company now and in six months? - Management believes the current model is replicable and scalable, with significant growth potential ahead, making it an exciting time for investors [52][56] Question: How does revenue recognition differ between models? - Revenue recognition varies based on the model, with acquisitions allowing for immediate recognition upon product shipment, while contractual alliances may involve profit-sharing arrangements [57]

Financial Data and Key Metrics Changes - For Q3 2025, revenue increased 76% to $6.8 million compared to $3.9 million in Q3 2024, and 78% sequentially from Q2 2025 [8] - For the nine months ended September 30, 2025, revenue increased approximately $2.3 million, or 20%, to $13.6 million compared to $11.3 million for the same period in 2024 [9] - Gross profit for Q3 2025 increased approximately $1.6 million to $3.9 million, with gross margin slightly decreasing to 58% from 60% in Q3 2024 [11] - Net loss increased to $5.4 million in Q3 2025 and $14.3 million for the first nine months of 2025 [12] Business Line Data and Key Metrics Changes - The increase in revenue was driven by a $2.2 million increase in OSA sleep testing services primarily from the Sleep Center of Nevada and $1.3 million from new treatment centers [8] - VIP enrollment revenue from the legacy business model decreased by $800,000, indicating a shift towards the new business model [9] Market Data and Key Metrics Changes - The company is currently servicing significantly less than 40% of the potential new patients being tested each month at Sleep Center of Nevada, indicating substantial growth potential [26] - Over 210,000 OSA patients have been tested and seen by SCN providers since 2019, with many legacy patients potentially seeking alternatives to CPAP [26] Company Strategy and Development Direction - The strategic pivot towards acquiring sleep medical practices and testing centers aims to increase patient access to Vivos technology and improve financial returns [20] - The establishment of Sleep and Airway Medicine Centers (SAMHSA Centers) is central to the new model, focusing on educating and evaluating patients for treatment [24] - Future initiatives include expanding diagnostic and treatment services, establishing a pediatric OSA program, and collaborating with specialty medical groups [32] Management's Comments on Operating Environment and Future Outlook - Management views Q3 2025 as a watershed quarter, indicating the company's ability to monetize its technology for treating sleep-related disorders [17] - The company expects revenue growth to continue as new dental providers and nurse practitioners are onboarded, with a projected ramp-up period of three to six months for optimal revenue levels [42][44] - Management believes the new model is replicable and scalable across multiple markets, with a focus on achieving cash flow break-even in the near future [50][56] Other Important Information - The company has secured $14.2 million in net cash from financing activities, with total liabilities of $23.1 million and cash and cash equivalents of $3.1 million as of September 30, 2025 [13] Q&A Session Summary Question: How should sales be modeled for the next few quarters? - Management expects top-line revenues to continue to grow as new providers are deployed, with a ramp-up period of three to six months for optimal revenue levels [41][44] Question: What are the reasonable operating expenses for the next quarter? - SAMHSA operations are expected to achieve contribution margins of 50%-60% at steady-state, with current expenses being higher due to upfront investments in personnel [46][47] Question: Update on cash flow break-even goals? - The goal is to achieve cash flow break-even, with expectations that profits from SAMHSA center operations will contribute to this goal in the near future [49][50] Question: How should investors view the company now and in six months? - Management believes the company has finally settled on a monetization model that leverages its technological advantages, with significant growth potential ahead [55][56]

Financial Data and Key Metrics Changes - For Q3 2025, revenue increased by 76% to $6.8 million compared to $3.9 million in Q3 2024, and 78% sequentially from Q2 2025 [7][9] - For the nine months ended September 30, 2025, revenue increased by approximately $2.3 million, or 20%, to $13.6 million compared to $11.3 million for the same period in 2024 [9][12] - Gross profit for Q3 2025 increased by approximately $1.6 million to $3.9 million, with gross margin slightly decreasing to 58% from 60% in Q3 2024 [11][12] Business Line Data and Key Metrics Changes - The increase in revenue was driven by a $2.2 million increase in OSA sleep testing services primarily from the Sleep Center of Nevada, and $1.3 million from new treatment centers [8][9] - VIP enrollment revenue from the legacy business model decreased by $800,000, indicating a shift towards the new business model [9][10] Market Data and Key Metrics Changes - The company is currently servicing significantly less than 40% of the potential new patients being tested each month at the Sleep Center of Nevada, indicating substantial growth potential [24] - Over 210,000 OSA patients have been tested and seen by SCN providers since 2019, with many legacy patients potentially seeking alternatives to CPAP [24] Company Strategy and Development Direction - The strategic pivot towards acquiring sleep medical practices and forming alliances is aimed at increasing market penetration and financial returns [19][20] - The establishment of Sleep and Airway Medicine Centers (SAMHSA Centers) is part of the strategy to educate and evaluate patients for treatment options [22][30] Management's Comments on Operating Environment and Future Outlook - Management views Q3 2025 as a watershed quarter, indicating a significant inflection point in the company's ability to monetize its technology for treating sleep-related disorders [16][19] - The company expects revenue growth to outpace expenses as new teams are deployed and operational efficiencies are realized [23][33] Other Important Information - The company has secured $14.2 million in net cash from financing activities, which will support its growth initiatives [13] - General and administrative expenses increased by approximately $5.7 million, primarily due to costs associated with the Sleep Center of Nevada operations [12] Q&A Session Summary Question: How should sales be modeled for the next few quarters? - Management expects top-line revenues to continue to grow as new dental providers and nurse practitioners are added to the teams [35] Question: What is the expected ramp-up time for revenue generation? - A ramp-up period of approximately three to six months is anticipated to reach optimized revenue levels [36] Question: What are the expected contribution margins for SAMHSA operations? - Steady-state operations are expected to yield contribution margins of 50%-60% [38] Question: What is the goal for cash flow break-even? - The goal is to achieve cash flow break-even, with ongoing efforts to manage growth and operational expenses [39] Question: How should investors view the company now and in six months? - Management believes the company has finally found a monetization model that aligns with its technological advantages, indicating strong future growth potential [41][42]

Revenue Performance - Revenue for Q3 2025 was $6.8 million, a 78% increase sequentially and a 76% increase year-over-year compared to Q3 2024's $3.9 million[5] - Total revenue for the three months ended September 30, 2025, was $6,783 million, a significant increase from $3,860 million in the same period of 2024, representing a growth of 76.5%[21] - Product revenue reached $2,195 million for the three months ended September 30, 2025, compared to $1,958 million in 2024, marking an increase of 12.1%[21] - Service revenue surged to $4,588 million for the three months ended September 30, 2025, up from $1,902 million in 2024, reflecting a growth of 141.5%[21] Profitability and Loss - Gross profit for Q3 2025 was $3.9 million, reflecting an increase from $2.3 million in Q3 2024, while gross margin declined to 58% from 60% year-over-year[5] - Gross profit for the three months ended September 30, 2025, was $3,937 million, compared to $2,334 million in 2024, indicating an increase of 68.8%[21] - The operating loss for Q3 2025 increased to $4.7 million from $2.6 million in Q3 2024[5] - Operating loss for the three months ended September 30, 2025, was $(4,734) million, widening from $(2,645) million in the same period of 2024[21] - Net loss for the three months ended September 30, 2025, was $(5,400) million, compared to $(2,616) million in 2024, representing an increase in loss of 106.8%[21] - Net loss per share (basic and diluted) for the three months ended September 30, 2025, was $(0.49), compared to $(0.40) in 2024[21] Expenses and Financial Position - Operating expenses for Q3 2025 were $8.7 million, a 74% increase from $5.0 million in Q3 2024, primarily due to increased headcount and depreciation expenses related to the SCN acquisition[5] - Total operating expenses for the three months ended September 30, 2025, were $8,671 million, up from $4,979 million in 2024, reflecting a rise of 74.5%[21] - Cash and cash equivalents decreased to $3.1 million as of September 30, 2025, down from $6.3 million at the end of 2024[5] - Stockholders' equity was $2.5 million as of September 30, 2025, compared to $8.0 million at the end of 2024[5] Strategic Initiatives - The acquisition of The Sleep Center of Nevada contributed $2.2 million in diagnostic sleep testing revenue and $1.3 million in treatment center revenue during Q3 2025[5] - Vivos plans to expand its model into additional major markets beyond Las Vegas through acquisitions or contractual alliances with sleep medical practices[3] - The company is actively working to add new sleep optimization teams in 2026 to reduce cash burn and create potential for profitable operations[4] - Vivos has entered into a management agreement with MISleep Solutions LLC to provide its treatments and services in Auburn Hills, Michigan, with patient services expected to begin in early December 2025[7] Shareholder Information - The weighted average number of shares outstanding (basic and diluted) increased to 10,963,590 for the three months ended September 30, 2025, from 6,615,320 in 2024[21] - Non-operating income (expense) included other expense of $(679) million for the three months ended September 30, 2025, compared to $(18) million in 2024[21]

Core Insights - Vivos Therapeutics reported a 78% sequential revenue growth in Q3 2025, driven by the first full quarter of operations from the Sleep Center of Nevada acquisition, with a year-over-year revenue increase of 76% [2][4] - The strategic pivot from a dental distribution model to direct affiliations and acquisitions of medical sleep practices is yielding positive results, as evidenced by the revenue contributions from the Sleep Center of Nevada [2][4] - The company is optimistic about growth potential in the Las Vegas area and plans to expand its model into other major markets [2][6] Financial Performance - Q3 2025 revenue reached $6.8 million, up from $3.9 million in Q3 2024, while revenue for the nine months ended September 30, 2025, was $13.6 million compared to $11.3 million in the same period of 2024 [4][23] - Gross profit for Q3 2025 was $3.9 million, reflecting an increase from $2.3 million in Q3 2024, with gross margins at 58% compared to 60% in the previous year [4][11] - Operating expenses rose to $8.7 million in Q3 2025, a 74% increase from $5.0 million in Q3 2024, primarily due to increased headcount and expenses related to the SCN acquisition [11][23] Strategic Initiatives - The acquisition of the Sleep Center of Nevada has introduced new revenue streams, contributing $2.2 million in diagnostic sleep testing revenue and $1.3 million in treatment center revenue during Q3 2025 [4][23] - Vivos is implementing an updated sleep practice affiliation model to collaborate with sleep centers that prefer not to be acquired, allowing them to offer Vivos' diagnostic and treatment options [5][6] - The company is actively seeking similar management agreements in other major markets to expand its reach and service offerings [6] Market Outlook - Vivos anticipates significant local market growth potential in Las Vegas, with patient bookings extending into February 2026 as they work to enhance operations and capacity [2][4] - The company plans to continue adding new sleep optimization teams in 2026, which is expected to reduce cash burn and pave the way for profitable operations [3][11]

Revenue Performance - Total revenue for Q3 2025 was $6,783,000, a 76% increase from $3,860,000 in Q3 2024[18] - Product revenue increased to $2,195,000 in Q3 2025, up 12% from $1,958,000 in Q3 2024[18] - Service revenue surged to $4,588,000 in Q3 2025, compared to $1,902,000 in Q3 2024, representing a 142% increase[18] - For the three months ended September 30, 2025, the company incurred a net loss of $5.4 million, compared to a net loss of $2.6 million for the same period in 2024[149] - Pro forma net revenue for the three months ended September 30, 2025, was $6.8 million, compared to $5.8 million for the same period in 2024[88] Financial Losses - Operating loss for Q3 2025 was $(4,734,000), compared to $(2,645,000) in Q3 2024, indicating a worsening of 79%[18] - Net loss for Q3 2025 was $(5,400,000), compared to $(2,616,000) in Q3 2024, representing a 106% increase in losses[18] - For the nine months ended September 30, 2025, the net loss was $14.276 million, compared to a net loss of $8.309 million for the same period in 2024, representing a 72% increase in losses[24] Assets and Liabilities - Total assets as of September 30, 2025, were $25,644,000, significantly up from $15,284,000 as of December 31, 2024[15] - Total liabilities increased to $23,112,000 as of September 30, 2025, compared to $7,330,000 at the end of 2024[15] - Stockholders' equity decreased to $2,532,000 as of September 30, 2025, down from $7,954,000 as of December 31, 2024[15] Cash Flow and Financing - Net cash used in operating activities was $11.451 million for the nine months ended September 30, 2025, compared to $9.751 million for the same period in 2024, indicating a 17% increase in cash outflow[24] - The company reported net cash provided by financing activities of $14.223 million for the nine months ended September 30, 2025, compared to $14.822 million for the same period in 2024, showing a slight decrease of 4%[24] - Cash and cash equivalents at the end of the year were $3.087 million, down from $6.311 million at the end of the previous year, reflecting a decrease of 51%[24] Strategic Acquisitions and Business Model - The company acquired all operating assets of The Sleep Center of Nevada for a total consideration of $6.0 million in cash and $1.5 million in common stock, marking a strategic expansion into sleep disorder treatment[29] - The company is exploring additional acquisitions and collaborations with medical sleep practices to expand its business model and revenue streams[37] - The company has shifted its focus to direct patient services, including home sleep screenings and telemedicine, under its new business strategy[32] Revenue Recognition and Customer Contracts - Revenue recognition follows ASC Topic 606, with legacy VIP enrollment revenue expected to continue through 2026[44] - Estimated customer life for VIP contracts ranges from 14 to 27 months, impacting revenue recognition timing[48] - Revenue from appliance sales is recognized upon transfer of control to the VIP, with the company acting as the principal in the transaction[59] Market and Operational Challenges - The Federal Reserve's elevated interest rates pose a risk to the company's revenue, earnings, and access to capital[207] - Changes in U.S. trade policy and tariffs may materially impact the company's sourcing strategy and competitiveness of contract manufacturers[205] - Ongoing geopolitical tensions, including the war in Ukraine and Middle East hostilities, could adversely affect demand for the company's products and capital market stability[209] Compliance and Regulatory Matters - The company received a notice from Nasdaq regarding non-compliance with the $2,500,000 minimum stockholders' equity requirement as of March 31, 2024[211] - Following a $7.5 million equity private placement, the company reported compliance with the equity requirement and received continued listing approval from Nasdaq[211] - The company is exploring additional equity capital financings to maintain compliance with Nasdaq's equity requirement[212]

Core Viewpoint - Vivos Therapeutics, Inc. is set to release its third quarter 2025 financial results and will discuss strategic collaborations that may impact revenue growth and cash burn during a conference call scheduled for November 19, 2025 [1][2]. Company Overview - Vivos Therapeutics, Inc. specializes in medical devices and healthcare services for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [5]. - The company has developed proprietary treatments and diagnostic procedures, with its devices cleared by the FDA for various severity levels of OSA in both adults and children [5]. - Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first for moderate to severe OSA in children [5]. Market Context - OSA affects over 1 billion people globally, with 90% undiagnosed, linking it to serious chronic health conditions [6]. - Traditional treatments like CPAP often fail to address the root causes of OSA, indicating a need for innovative solutions [6]. Strategic Initiatives - Vivos aims to enhance its market position through technology, education, and collaborations with sleep healthcare providers to better address OSA patients' needs [7]. - The company promotes The Vivos Method, a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical solution for OSA [8].

Company Overview - Vivos Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders via live webcast, emphasizing the shift towards virtual meetings for improved accessibility and attendance [1][3]. Leadership and Structure - Kirk Huntsman serves as the Chief Executive Officer and Chairman of the Board of Directors, with Brad Amman acting as Chief Financial Officer and Secretary of the meeting [2]. Voting and Participation - Stockholders of record as of September 8, 2025, are eligible to vote either by proxy or virtually during the meeting, allowing for greater participation [3]. - Shareholders who have already submitted a proxy and do not wish to change their vote are not required to vote again, streamlining the voting process [4].